Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib in Patients with Psoriatic Arthritis Biotech Investing
Bristol Myers Squibb Receives European Commission Approval for Opdivo plus Yervoy with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Biotech Investing
AbbVie to Highlight Blood Cancer Leadership and Advancing Oncology Pipeline at the ASH 62ND Annual Meeting Biotech Investing
Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020 Biotech Investing
Bristol Myers Squibb Data at ACR Convergence 2020 Underscore Commitment to Advancing Science for Patients with Difficult-to-Treat Immune-Mediated Diseases Biotech Investing
Health Canada Provides Authorization Letter for Naturally Splendid JV, PLASM Pharmaceutical to Begin COVID-19 Phase 2 Clinical Trial Biotech Investing
